St John McGrath
Chairman chez Bioshin Ltd.
Profil
St John Donnie McGrath is currently the Executive Chairman & President at BioShin Ltd., Director at Artizan Biosciences, Inc., and Venture Partner at OrbiMed Advisors Private Equity.
Previously, he worked as the Director-Global Clinical Research at Bristol Myers Squibb Co. from 2005 to 2008, Vice President-Business Development at Bristol-Myers Squibb Pharmaceutical Research Institute from 2013 to 2017, Chief Corporate Strategy & Business Development at Biohaven Pharmaceutical Holding Co. Ltd.
from 2017 to 2022, and Assistant Professor at Tufts University School of Medicine from 1995 to 2005.
Dr. McGrath received his undergraduate degree from University College Dublin, his doctorate from Royal College of Surgeons, and another doctorate from Harvard T.H.
Chan School of Public Health.
Postes actifs de St John McGrath
| Sociétés | Poste | Début |
|---|---|---|
Artizan Biosciences, Inc.
 Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Director/Board Member | - |
Bioshin Ltd.
 Bioshin Ltd. BiotechnologyHealth Technology Part of Biohaven Ltd., BioShin Ltd. is a biopharmaceutical company based in Shanghai, China. The Chinese company is advancing the Biohaven clinical portfolio in the Asia-Pacific region, excluding Japan and South Korea. BioShin is focused on discovering, developing, and commercializing novel treatments for patients with neuro-immune diseases in China and the Asia-Pacific region. The private company has a proven and established late-stage portfolio from its strategic partner, Biohaven Pharmaceuticals Inc. in the US, and is poised to quickly launch novel medicines for patients in need. The CEO of the company is Karl Lintel. | Chairman | - |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Private Equity Investor | 01/01/2023 |
Anciens postes connus de St John McGrath
| Sociétés | Poste | Fin |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Corporate Officer/Principal | 01/12/2022 |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/01/2017 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/04/2008 |
| Tufts University School of Medicine | Corporate Officer/Principal | 01/04/2005 |
Formation de St John McGrath
| University College Dublin | Undergraduate Degree |
| Royal College of Surgeons | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 5 |
|---|---|
OrbiMed Advisors Private Equity
OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
| Bristol-Myers Squibb Pharmaceutical Research Institute | |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Artizan Biosciences, Inc.
Artizan Biosciences, Inc. Medical/Nursing ServicesHealth Services Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT. | Health Services |
Bioshin Ltd.
Bioshin Ltd. BiotechnologyHealth Technology Part of Biohaven Ltd., BioShin Ltd. is a biopharmaceutical company based in Shanghai, China. The Chinese company is advancing the Biohaven clinical portfolio in the Asia-Pacific region, excluding Japan and South Korea. BioShin is focused on discovering, developing, and commercializing novel treatments for patients with neuro-immune diseases in China and the Asia-Pacific region. The private company has a proven and established late-stage portfolio from its strategic partner, Biohaven Pharmaceuticals Inc. in the US, and is poised to quickly launch novel medicines for patients in need. The CEO of the company is Karl Lintel. | Health Technology |
